IRD (Opus Genetics) Other Financing: $0.64 Mil (TTM As of Mar. 2026)


IRD Opus Genetics Inc IRD
24 GF Score
Price $4.00
GF Value $0.37
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Opus Genetics Other Financing?

Opus Genetics IRD +7.38% 24 Other Financing is $0.64 Mil as of Mar. 2026. GuruFocus rates IRD with a GF Score™ of 24/100 and a GF Value™ of $0.37 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Opus Genetics's Other Financing for the three months ended in Mar. 2026 was $0.38 Mil.

Opus Genetics's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was $0.64 Mil.

Opus Genetics Other Financing Historical Data

* Premium members only.

The historical data trend for Opus Genetics's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Opus Genetics Other Financing Chart

Opus Genetics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial -1.42 -0.10 -0.25 -0.23 15.39

Opus Genetics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.11 0.00 -0.67 0.93 0.38
IRD
24GF Score
Opus Genetics Inc IRD
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Opus Genetics Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.64 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $0.64 Mil mean?
Opus Genetics (IRD) has a Other Financing of $0.64 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Opus Genetics and its competitors.
Is Opus Genetics' Other Financing too high?
Opus Genetics' current Other Financing is $0.64 Mil. Overall, Opus Genetics has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Opus Genetics' Other Financing compare to IFRX and RGNX?
Opus Genetics' Other Financing of $0.64 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Opus Genetics and its competitors. Opus Genetics's current Other Financing is $0.64 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Opus Genetics stock overvalued right now?
Based on GuruFocus' analysis, Opus Genetics (IRD) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.37, compared to a current price of $4.00 — trading 981.1% above its estimated fair value. The current Other Financing is $0.64 Mil. Opus Genetics' overall GF Score™ is 24/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Opus Genetics (IRD), the current Other Financing is $0.64 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Opus Genetics (IRD) Overvalued in 2026?

Based on GuruFocus' analysis, Opus Genetics stock appears to be overvalued. The current stock price of $4.00 is trading 981.1% above its estimated GF Value™ of $0.37. GuruFocus considers Opus Genetics to be Significantly Overvalued.

Key valuation signals for IRD:

  • Other Financing: $0.64 Mil
  • GF Value™: $0.37 vs. price of $4.00 (981.1% above fair value)
  • GF Score™: 24/100 with 4 warning signs

No single metric tells the full story. See the IRD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Opus Genetics Business Description

Other Exchanges R3X1:Germany
Address 8 Davis Drive, Suite 220, Durham, NC, USA, 27713
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
24GF Score

Get the complete analysis for IRD

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.00
Price
$0.37
GF Value